The Pfizer Clinical Research Unit (PCRU) in Brussels is seeking healthy participants for a clinical trial of a study drug. 

This study will measure how much of the study drug is in your blood after you receive a single dose.

Who may participate

Who may participate

This study is seeking healthy male and female participants. Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health. You may not take part in this study if:

  • You are outside of the limits of age (18-65 years) or weight (minimum of 50 kg or 45 kg for the Japanese cohort), or Body Mass Index (16-32 kg/m2).
  • For the Japanese cohort: You do not have 4 biological Japanese grandparents who were born in Japan.
  • For the Chinese cohort: You do not have 4 biological Chinese grandparents who were born in China.

There are other requirements for participation in this study. Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process. 

Condition

Healthy

Age

18 to 65

Sex

Male/female

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

What to expect

 

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium. 

This study will have 2 Parts:

  • A part with Single Ascending (escalating) doses, referred to as the ‘SAD Part’
  • A part with Multiple doses, referred to as the ‘MD Part’


If you take part in the SAD Part, you will need to come to the study centre up to 9 times. There are 8 consecutive overnight stays. The total duration of the study part is 14 weeks. 
If you take part in the MD Part, you will need to come to the study centre up to 14 times. There are 9 overnight stays in 3 discontinuous periods. The total duration of the study part is 22 weeks.

You will be screened within 28 days prior to the first dose of study intervention.

Throughout the study, staff will closely monitor your health status and collect data.

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.


 

View calendar

How long is the study?

Approximately 14 weeks

Compensation

Up to € 5.510 , plus travel fees